A phase II trial to evaluate the efficacy and safety of GDC-0276 in patients with pain

Trial Profile

A phase II trial to evaluate the efficacy and safety of GDC-0276 in patients with pain

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs GDC 0276 (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2017 According to a Xenon Pharmaceuticals media release, Genentech plans to initiate Nav1.7 pain program in 2017.
    • 18 Mar 2016 New trial record
    • 15 Mar 2016 According to Xenon Pharmaceuticals media release, Genentech plans to initiate this phase II trial in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top